Navigation Links
GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
Date:2/8/2010

ontain proteins that mimic more than half of the components of the AIDS virus, but cannot cause AIDS. This multi-protein approach is designed to elicit a broad multi-target protective T cell response. The Env protein is designed to elicit a protective antibody response against the natural form of the virus envelope glycoprotein as well as protective T cells.

About HIV/AIDS

AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation.  33 million people are currently infected globally and it is estimated that there will be 2.5 million new infections this year.  Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus.  Every 9 1/2 minutes, someone in the U.S. is infected with AIDS. Globally, HIV is the top killer among women of reproductive age.

HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world.  Clade B is the predominant subtype in North America.  Globally, most infections involve subtypes AG, B, and C. In 2008, antiretroviral treatment in low and middle income countries was restricted to about 3 million people. In the United States, about 50% of those who are infected are estimated to be on drug treatment.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents.  GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications.  GeoVax AIDS vaccines are designed for use in uninfected people to prevent acquisition of HIV-1 and limit the progression to AIDS should a person become infected. GeoVax AIDS vaccines also may be effective as a th
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
7. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
10. GeoVax Secures $10 Million Financing Commitment
11. GeoVax Reports Progress on Its AIDS Vaccine Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... subscriptions from institutional and accredited investors for a ... of common stock and 3.35 million common stock ...
(Date:7/27/2015)... 27, 2015 Bloomage BioTechnology Corporation Limited ("Bloomage" ... cooperation with the South Korean BioTech Company Medytox Inc. ... Medybloom to develop and promote Type A Botulinum Toxin ... Medytox, the Botulinum Toxin brand, occupies ... the fourth company in the world successfully developed and ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3
... BEVERLY, Mass., March 8, 2011 Cellceutix Corporation (Pink ... has entered into a Confidential Disclosure Agreement (CDA) pertaining ... world,s largest pharmaceutical companies. Cellceutix CEO, ... to be signing a CDA on a compound before ...
... Inc. (Nasdaq: CPIX ), a specialty pharmaceutical ... announced fourth quarter and full year 2010 financial results. ... December 31, 2010, net revenue was $12.8 million, up 20% ... quarterly revenue growth was largely driven by 16% year-over-year growth ...
Cached Medicine Technology:Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
(Date:7/28/2015)... ... July 28, 2015 , ... VAZATA, a ... expanding their cloud presence to support their rapidly growing business. , Headquarted in ... been serving the Dallas/Fort Worth area for almost 50 years. HeartPlace is recognized ...
(Date:7/28/2015)... ... 2015 , ... Please join us for the 5th Annual Step for Hope 5K Run/Walk ... Avenue and Lies Road in Carol Stream. All are welcome. , Now in its ... and help to support individuals and families affected by a brain aneurysm. , “We ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... a number of publications, including Runner’s World Magazine, is plantar fasciitis . ... constant pain. , Designed by a professional athletic trainer, the Zensah Ankle ...
(Date:7/28/2015)... ... July 28, 2015 , ... Intellitec Solutions has been named by ... of Value Added Resellers of ERP Software is a look at the firms that ... honor represents the second such award in 2015 for Intellitec Solutions, following being named ...
(Date:7/28/2015)... Saint Louis, MO (PRWEB) , ... July 28, 2015 , ... ... and back pain comes in as a close second. Clients suffering from headaches and ... help clients get started with chiropractic treatment, The Joint 's nine offices in ...
Breaking Medicine News(10 mins):Health News:HeartPlace Announces Cloud Expansion with VAZATA 2Health News:HeartPlace Announces Cloud Expansion with VAZATA 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2Health News:The Joint St. Louis Offers “2 for Thursday” Special, Chiropractic Care Services, Affordable Back Pain Relief 2
... who receive compounds that stimulate white blood cell production ... an increased// risk of developing a type of leukemia ... new study in the February 7 Journal of the ... risk of the conditions is very small, but that ...
... remains a dreaded disease even today. But whether patients survive ... much they can afford to spend// on the drugs, according ... to ration life-saving cancer treatment, and some Canadians will live ... said the Cancer Advocacy Coalition of Canada report. ...
... found that wisdom in old age depends on a fresh ... that when mature mice learn a new task, their newly ... old ones, the New Scientist reported on its website. ... the Hospital for Sick Children in Toronto, Canada, injected a ...
... that video games that contain high levels of action, such ... ,Researchers at the University of Rochester have shown that people ... day over the course of a month improved by about ... visual acuity test similar to ones used in regular ophthalmology ...
... A recent survey identifies teen’s online behavior associated ... strangers online are more likely to become// victims ... personal information on the Internet. The report was ... Pediatrics & Adolescent Medicine, one of the JAMA/Archives ...
... in the on-line journal PLoS Biology concluded that the low ... central nervous system to// prematurely shut down. ... molecular trigger for the effects of toxicant exposure, may give ... new methods of evaluating the safety of chemicals. ...
Cached Medicine News:Health News:Growth Factors Given With Chemotherapy may Increase Risk of Blood Diseases 2Health News:Growth Factors Given With Chemotherapy may Increase Risk of Blood Diseases 3Health News:Call for a National 'Drugs Funding Program' for Cancer Treatment in Canada 2Health News:Action Video Games Improves Vision 2Health News:Teens More Likely to Become Victims of Online Harassments 2Health News:Environmental Toxicants Target Stem Cells 2Health News:Environmental Toxicants Target Stem Cells 3
... The DNA Expert: Detection of PCR, cDNA and ... an optimal microplate reader for a variety applications ... The instrument is suitable to handle assays in ... PCR tubes Cuvettes ...
... From solution to cell based assays, in ... non-isotopic method of detection, Fusion is the ... plus the capability to use the AlphaScreen ... modes in one system: Reads AlphaScreen ...
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements....
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
Medicine Products: